Comparative Safety Analysis of Serious Adverse Drug Events in North America: A 19-Year Study of FDA and Canadian Vigilance Databases

被引：0
|
作者：
Chalabianloo, Niaz [1 ,2 ,3 ]
Sedig, Kamran [3 ]
Muanda, Flory Tsobo [1 ,2 ,4 ,5 ]
机构：
[1] Western Univ, Dept Physiol & Pharmacol, London, ON, Canada
[2] ICES Western, London, ON, Canada
[3] Western Univ, Dept Comp Sci, London, ON, Canada
[4] Lawson Hlth Res Inst, London, ON, Canada
[5] Western Univ, Dept Epidemiol Biostat, London, ON, Canada
来源：
DRUG SAFETY | 2024年 / 47卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
134
引用
收藏
页码：1376 / 1377
页数：2
相关论文
共 36 条
  • [1] Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database
    Sonawane, Kalyani B.
    Cheng, Ning
    Hansen, Richard A.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (07): : 682 - 690
  • [2] SERIOUS ADVERSE DRUG EVENTS REPORTED TO THE FOOD AND DRUG ADMINISTRATION (FDA): ANALYSIS OF THE FDA ADVERSE EVENT REPORTING SYSTEM (FAERS) 2006-2011 DATABASE
    Sonawane, K. B.
    Hansen, R. A.
    VALUE IN HEALTH, 2015, 18 (03) : A86 - A86
  • [3] Long-term safety of lanthanum carbonate in the real word: a 19-year disproportionality analysis from the FDA Adverse Event Reporting System
    Ying, Mengjia
    Shi, Jian
    Ling, Yahao
    Shi, Tao
    Liao, Lele
    Cao, Linhui
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [4] Pediatric Drug Safety Surveillance in FDA-AERS, a Description of Adverse Events: A GRiP Study
    de Bie, Sandra
    Straus, Sabine M. J. M.
    Verhamme, Katia M. C.
    Ferrajolo, Carmen
    Bonhoeffer, Jan
    Wong, Ian
    Sturkenboom, Miriam C. J. M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 381 - 381
  • [5] Safety evaluation of cephalosporins based on utilization and adverse drug events: analysis of two databases in China
    Ren, Xiuhua
    Liu, Dong
    Ding, Nan
    Huang, Kun
    Xiong, Yongshan
    Du, Guang
    Zeng, Fandian
    EXPERT OPINION ON DRUG SAFETY, 2012, 11 (05) : 689 - 697
  • [6] Safety Analysis of Adverse Drug Reactions in United States: A 21-Year descriptive Study of FDA Adverse Event Reporting System
    Chalabianlo, Niaz
    Ahmadi, Fatemeh
    Abdullah, Sheikh
    Sedig, Kamran
    Muanda, Flory Tsobo
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 307 - 308
  • [7] A DISPROPORTIONALITY ANALYSIS OF THE SERIOUS ADVERSE DRUG EVENTS ASSOCIATED WITH GENE THERAPY PRODUCTS USING THE FDA ADVERSE EVENT REPORTING SYSTEM (FAERS)
    Ghanem, B.
    Fleming, M.
    Brown, L. M.
    Rodriguez-Monguio, R.
    Seoane-Vazquez, E.
    VALUE IN HEALTH, 2023, 26 (06) : S237 - S237
  • [8] Immunotherapy-related adverse events (irAEs): extraction from FDA drug labels and comparative analysis
    Wang, QuanQiu
    Xu, Rong
    JAMIA OPEN, 2019, 2 (01) : 173 - 178
  • [9] Survey of serious adverse events and safety evaluation of oral anticancer drug treatment in Japan: A retrospective study
    Kawasumi, Kenji
    Kujirai, Azusa
    Matsui, Reiko
    Kawano, Yohei
    Yamaguchi, Masakazu
    Aoyama, Takao
    MOLECULAR AND CLINICAL ONCOLOGY, 2021, 14 (01) : 1 - 9
  • [10] A comparative analysis on serious adverse events reported for COVID-19 vaccines in adolescents and young adults
    Cappelletti-Montano, Beniamino
    Demuru, Giuseppe
    Laconi, Ezio
    Musio, Monica
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
1234